The CTChip® FR
The microfluidic biochip captures CTCs based on inertial characteristics such as size and deformability, relative to other blood components, by using Dean Flow Fractionation (DFF). Through the DFF process, the cells are focused within the microfluidic channels of the CTChip® FR, with larger cells along the inner wall and the smaller cells away from it. This label-free approach ensures effective, continuous and quick separation while retaining cell viability thus lending itself to a myriad of downstream applications.
NewsGenomeWeb Feature: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership to develop CTC CoRE in the U.S. PR Newswire: John Wayne Cancer Institute, and Clearbridge BioMedics announce partnership to develop Circulating Tumor Cell Centre of Research Excellence in the U.S. BioSpectrum: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership
22-23 AUGUST 2017 | SEOUL, S.KOREA | PRESENTATION & BOOTH #3Read more